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Objective: Prospective observational study of mycophenolate mofetil (MMF) treatment in 
patients with diffuse progressive cutaneous Systemic Sclerosis (SSc) of recent onset. 
 
Methods: Twenty five previously untreated consecutive patients with recent onset (<24 months) 
diffuse progressive cutaneous SSc received MMF as the only disease-modifying therapy. 
Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from 
initiation of MMF to study end. Pulmonary function tests performed at the same institution 
before therapy and at study end were available in 15 patients. Histopathology and real time PCR 
assessment of fibrosis-related gene expression were performed before and after treatment in skin 
biopsies from 3 patients. 
 
Results: At 18.2±8.73 months of MMF therapy (median 2000 mg/day) the mRSS decreased 
from 24.56±8.62 to 14.52±10.9 (p=0.0004) and the affected BSA from 36±16% to 14±13.3% 
(p=0.00001). Pulmonary function tests remained stable from initiation of MMF to the end of the 
study. Skin histopathology showed a remarkable reduction in fibrotic tissue accumulation. Real 
time PCR of skin biopsies demonstrated a marked decrease in expression of fibrosis-related 
genes. 
 
Conclusion: Patients with diffuse progressive cutaneous SSc of recent onset treated with MMF 
experienced marked improvement in skin involvement and stabilization of pulmonary function. 
Skin biopsies from 3 patients demonstrated histopathological improvement and decreased 
expression of fibrosis-related genes.  
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Introduction 
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease characterized by increased 
collagen deposition in skin and multiple internal organs, prominent vascular and endothelial 
abnormalities and humoral and cellular immune dysregulation (1-3). The introduction of target 
organ specific therapies has substantially decreased Systemic Sclerosis (SSc) morbidity and 
mortality.  In contrast, most studies of potential disease-modifying agents have shown negative 
results and currently there is no generally accepted SSc disease modifying therapy.  
 
A major challenge for the evaluation of effectiveness of therapeutic interventions in SSc are the 
heterogeneity and variable course of the disease. To mitigate the effects of SSc course variability 
and following the paradigm that early intervention is crucial for halting fibrosis most recent 
studies selected patients with recent onset of disease (5-9). Disease of recent onset has been 
defined in different ways in various studies although a cut-off point of 18-24 months from the 
appearance of clinically detectable skin induration is generally accepted. Furthermore, patients 
should have substantial skin involvement at treatment initiation to allow detection of 
improvement employing the outcome measure tools currently available.   
 
Mycophenolate mofetil (MMF) is an immunosuppressant agent that inhibits proliferative 
responses of T and B lymphocytes as well as antibody production by B lymphocytes. It is 
indicated for prevention of organ rejection following allogeneic cardiac, hepatic and renal 
transplants (10). It is also used for induction and maintenance therapy of lupus nephritis (11,12). 
Furthermore, there is evidence that MMF can inhibit fibrosis by acting either directly on 
fibroblasts (13) or by inhibiting fibroblast proliferation (14), and by reducing tissue accumulation 
of activated myofibroblasts (15).  
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Several studies including a recent assessment of 98 patients have described encouraging results 
of MMF treatment for SSc (16-20). In contrast, a recent observational trial failed to show 
significant differences between four different therapeutic approaches, three of which included 
MMF (21). Here, we describe a prospective observational study of MMF for the treatment of 
SSc in patients with recent onset of progressive diffuse cutaneous involvement. In contrast with 
other published studies (16-20) the patients included in our study had not received any previous 
immunosuppresive, immunomodulating, or antifibrotic therapy, and none of the patients received 
any other disease modifying therapy during the study.  
 
Patients and Methods 
Patient cohort.  From December 2006 to December 2009, every new patient with diffuse and 
rapidly progressive SSc of recent onset evaluated at our institution was offered treatment with 
MMF as disease modifying monotherapy. Only patients with less than 2 years of disease and 
mRSS of greater than 12 points who had not received any previous immunosuppressive, 
immunomodulatory, or anti-fibrotic therapy were included. Despite the consecutive enrollment 
design not all qualifying patients received MMF owing to diverse reasons including most 
commonly the denial of insurance reimbursement.  
 
All patients received 500mg twice a day MMF for 3 to 4 weeks and then the dose was escalated 
to 1-1.5 g twice a day.  Other concomitant medications included calcium channel blockers, 
angiotensin converting enzyme inhibitors, proton pump inhibitors, statins and low dose aspirin. 
The effects of MMF on the extent and severity of skin involvement employing the modified 
Rodnan Skin Score (mRSS) and an estimate of extent of affected body surface area (BSA) were 
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assessed as described previously (22). The effects of MMF on SSc severity employing some of 
the categories of Medsger’s severity scale (23) were also examined. 
 
The inclusion criteria were: (i) time from onset of clinically detectable skin  induration to 
initiation of MMF less than 24 months; (ii) diffuse skin involvement at initiation of MMF 
affecting the trunk and ⁄or arms and legs proximally to the elbows and ⁄or knees with a mRSS 
greater than 12; (iii) no previous treatment with MMF, D-penicillamine, bovine collagen, 
cyclophosphamide or any other putative SSc disease modifying drug or intervention; and (iv) the 
presence of progressive skin involvement based on information provided by the referring 
rheumatologist or by sequential examination at our center. 
 
The exclusion criteria were: (i) skin involvement confined to face or acral regions of the body 
(limited cutaneous SSc); (ii) Eosinophillic fasciitis, Nephrogenic Systemic Fibrosis, or other 
scleroderma –like diseases; (iii) Mixed connective tissue disease and overlap syndromes; (iv) 
prior or current therapy with any other immunosupressant or antifibrotic agent and (v) poor 
compliance to medications or follow up.  
 
Study entry was the initiation of MMF treatment and end of study was the last recorded visit. For 
data analysis only patients who were followed up for at least 6 months were included. 
 
Assessment of MMF effects on cutaneous and visceral involvement. The extent and severity of 
skin involvement was assessed by the mRSS, and the extent of affected BSA was assessed by the 
rule of nines employing a burns victim diagram as described previously (22). These parameters 
were recorded every 3-6 months during the treatment follow up. Pulmonary function tests, 
including total lung capacity (TLC) and diffusion capacity for carbon monoxide (DLCO) were 
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monitored every 6 to 12 months during the study. Although chest computerized tomography 
(CT) is part of the evaluation and management for all SSc patients at our center CT findings 
were not systematically followed up. Percentages and means ± SD were used to describe the 
cohort’s demographics. A paired two-tail Student’s t test was used to compare data during the 
study period. Because skin involvement continues to increase in extent and severity for a 
variable length of time following initiation of therapy in patients with diffuse SSc of recent onset 
comparisons of skin involvement were performed between the initial vs final scores and between 
the maximal (peak) vs final scores. 
 
Effects of MMF on skin histopathology and fibrosis-related gene expression. Pre- and post-
treatment skin biopsies were performed in three patients with their informed consent. Punch 
biopsy samples were obtained from affected skin in the dorsum of the forearm. The post-
treatment samples were from an area removed approximately 5mm from the initial skin biopsy. 
Histopathology assessment was performed in hematoxillin eosin stained skin biopsy samples. 
Total RNA was extracted from all the biopsies using RNeasy Fibrous Tissue Kit (Qiagen, 
Valencia, CA). Each sample was retro-transcribed using SuperScript II reverse transcriptase 
(Invitrogen) and real-time quantitative PCR (rt-PCR) was performed for the expression of 
COL1A1, COL1A2, COL4A1, COL14A1, CTGF, FN1, αSMA and TGF- β1. Sequence specific 
primers (Table 1) were designed using PrimerQuest (Integrated DNA Technologies, Coralville, 
IA). Rt-PCR was performed using SYBR green with an ABI Prism 7900 system (Applied 
Biosystems, Carlsbad, CA). The mRNA expression level was normalized by 18s ribosomal 
RNA. 
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Statistical Analysis. Statistical analysis was performed using a paired Student’s t test. A p value 
of < 0.05 was considered statistically significant. Statistical analyses were performed using Excel 
and GraphPad Prism programs. 
Results  
Demographics. There were 35 patients with progressive SSc who fulfilled the classification 
criteria for SSc of the American College of Rheumatology (24) and the criteria of LeRoy et al. 
(25) for the clinical subset of diffuse cutaneous SSc. All patients had disease of recent onset and 
had not received any prior immunomodulatory or immunosuppressive therapy nor any putative 
anti-fibrotic agent or intervention.  Twenty five patients met the inclusion and exclusion criteria 
and were followed at our institution for at least 6 months. The mean ±SD age at initiation of 
treatment was 48.6±14.5 years. The majority of the patients were caucasians (76%) with a 
smaller proportion of African Americans (12%). The autoantibody profile indicated that 100% 
had a positive antinuclear antibody (ANA), by immunofluorescence and 36% (9 patients) 
harbored anti-Scl-70 antibodies. The remaining patients were ANA positive but Scl-70 and 
anticentromere antibody negative. Analysis for RNA polymerase I/III or other SSc specific 
antibodies were not performed in all patients studied. The average duration of therapy was 18.2 ± 
8.73 months, and 18 out of 25 (72%) were treated for longer than 1 year. The average dose of 
MMF was 2.02 g/day. Only 3 patients had received less than 2 g/d owing to gastrointestinal side 
effects. 
 
Clinical assessment of skin involvement and pulmonary function. Clinically detectable skin 
induration was first noted at a mean ± SD of 14.1 ± 7.3 months prior to study entry. At the 
initiation of therapy the mRSS was 24.56 ± 8.62 units and the affected BSA was 36 ±16%.  In 
the vast majority of patients a worsening of mRSS and extent of affected BSA was noted 
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following entry into the study reaching a peak from 3-6 months after initiation of MMF therapy. 
The average time from the first detectable skin involvement to the maximal involvement 
(considered as the maximal mRSS) was 20.1 months and the interval between initiation of 
treatment to peak mRSS was 6.4 months. Maximal mean ± SD mRSS and BSA were 27.36 ± 
9.71 points and 38 ± 15.4%, respectively. The increase in mRSS from the initiation of therapy to 
maximal involvement was statistically significant (p=0.0065). Although the increase in BSA 
value displayed a similar trend it did not reach statistical significance. (p= 0.069). A significant 
reduction of the mRSS and affected BSA was noted from the beginning of therapy to the end of 
the study. The mRSS decreased from 24.56 ± 8.62 at entry to 14.52 ± 10.9 (p=0.004) and the 
BSA decreased from 36 ± 16% at entry to 14 ± 13.3% (p=0.00001). A more dramatic change 
was observed when the peak involvement was compared with the involvement at the end of the 
study.  The values observed were 27.36 ± 9.7 vs 14.52 ± 10.9 (p= 2.5x10-6) for the mRSS and 38 
± 15.4% vs 14 ± 13.3% (p= 9.2x10-7). 
Figure 1 shows the mRSS values and extent of BSA treatment initiation (point 1), at peak 
involvement (point 2), and at last follow up (point 3). The changes in affected BSA in three 
patients in whom skin biopsies were obtained before initiation of MMF therapy and at the end of 
the study are pictured in Figure 2. The modified Medsger Severity Score was assessed in all 
patients in the study, however, the values represent an underestimate of the severity of the 
disease since not all patients with gastrointestinal symptoms were examined by endoscopy or 
barium swallow and muscle involvement was not routinely evaluated. Scores for organ 
involvement measured by the Medsger Severity Score at initiation of treatment compared with 
the scores at study end did not reach statistical significance with the exception of the skin index 
that demonstrated a significant reduction (2.2 ± 0.71 versus 1.52± 0.77, p=0.0003).  
 9 
 
The results of pulmonary function tests were analyzed in 15/25 patients who had pre- and post-
treatment pulmonary function tests performed at the same institution and were, therefore, 
consistent in methodology and equipment utilized. The results in these patients showed that TLC 
was 89.47 ± 16.61 % of predicted at study entry compared with 85.33 ± 17.34% at study end 
(p=0.13). In this subgroup of 15/25 patients only 3 patients showed a decrease in their TLC 
values greater than 10%. The results for DLCO were 69.0% ± 17.51% of predicted at study entry 
compared to 70.47% ± 18.84% of predicted at study end (p=0.45). 
 
Tolerability and Adverse Events.  All patients tolerated MMF treatment well and in no case was 
MMF discontinued owing to intolerance or side effects although in 3 of the 25 patients studied 
the dose was reduced to 1-1.5g/day because of gastrointestinal side effects. Ten patients 
developed at least one adverse event during MMF treatment. A total of 13 events were recorded. 
The most common events were diarrhea (3) and upper respiratory infections (3), followed by 
lymphopenia (2), and urinary tract infection (2). One of these 10 patients required a dose 
adjustment because of leukopenia. One of the patients in the study died at 18 months of entry. 
The cause of dead was a severe and rapidly progressive dilated cardiomyopathy of unkown 
etiology. Although it is very unlikely that this event was related to MMF treatment the possibility 
that it represented an abrupt deterioration of SSc cardiac involvement or a viral infection 
possibly related to immunosupression can not be conclusively established. However, at her last 
evaluation following 9 months of MMF therapy and approximately 10 months before her demise 
there was a clear reduction in both mRSS and total BSA thus, rendering the possibility that her 
demise was SSc related less likely. 
Skin histopathological analysis and assessment of fibrosis-related gene expression.  
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Histopathological examination and analysis of fibrosis-related gene expression were performed 
in pre- and post-treatment skin biopsies obtained from 3 patients. As illustrated in Figure 3, 
hematoxyllin-eosin staining showed a remarkable decrease in the abundance and thickness of 
collagen bundles and in their compact appearance in the dermis. Similar findings were observed 
in skin biopsies stained with Masson’s Trichrome (not shown). There was also very noticeable 
re-appearance of hair follicles and sweat and sebaceous glands in the post-treatment biopsies. 
Analysis of relative gene expression by real time quantitative PCR, demonstrated a marked 
decrease in the relative expression of numerous fibrosis-related genes including COL1A1, 
COL1A2, COL 4A1, COL 14A1, CTGF, FN1, αSMA and TGF- β1. (Figure 4). 
 
Discussion 
Mycophenolate mofetil, through its biologically active molecule, mycophenolic acid exerts 
potent antiproliferative properties resulting from the reversible inhibition of inosine 
monophosphate dehydrogenase (IMPDH).  Given the higher sensitivity of the lymphocyte 
IMPDH isoform, MMF exerts its effects by causing preferential lymphocyte suppression.  On the 
other hand, recent studies have shown that MMF is also able to decrease fibroblast proliferation, 
an effect which appears to be mediated mainly by IMPDH dependent pathways although IMPDH 
independent pathways can also play a role (14,15). It also has been shown that MMF is capable 
of direct inhibition of collagen production (13). 
The observed degree of improvement of mRSS in the study described here correlates well with 
prior studies by Derk et al. (19) and Le et al. (20) who found a reduction of 14.1 and 7.6 points in 
the mRSS of patients treated with MMF, respectively. Given the heterogeneous SSc course,  the 
greater than 10 point mRSS improvement and the 23% reduction in affected BSA observed here 
are likely clinically significant for this population of previously untreated patients with SSc of 
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recent onset with diffuse cutaneous involvement and usually progressive clinical course. 
Furthermore, these results are also superior to our previously published data on D-penicillamine 
in a similar population (22). These results are also superior to the spontaneous reduction in 
mRSS observed in the placebo control group (-4.6) and in the relaxin-treated group (-4.4) in a 
recently published study describing the results of a 24 week randomized control trial of human 
recombinant relaxin in a population of SSc patients similar to the one we studied here (26) and to 
the -3 point reduction at 15 months in either placebo or treated group in patients with early phase 
SSc entering the bovine type I collagen randomized control trial (27). 
The clinical improvement we observed correlated well with a remarkable decrease in 
histopathological fibrosis, re-appearance of dermal hair follicles and sebaceous and sweat glands, 
as well as, with a marked reduction in the expression of numerous fibrosis-related genes in 
samples from three patients in whom skin biopsies were obtained before and after therapy.  Of 
importance was the observation that MMF treatment prevented pulmonary function deterioration 
in this population with diffuse SSc of recent onset in whom substantial and significant 
deterioration of lung function is highly likely. However, it should be emphasized that the cohort 
studied here had only a mild baseline decrease in TLC at study entry, a variable which may have 
contributed to slow progression of pulmonary function deterioration as described by Plastiras et 
al. (28). The stabilization of lung involvement as assessed by comparison of pulmonary function 
tests from initiation of MMF treatment to the end of the study is similar to the results recently 
describe by Simeon-Aznar et al in 14 consecutive SSc patients who were treated with 1.5g of 
MMF for 12 months (29). 
Although the number of patients described here is not large, there are several strengths to our 
study including the prospective observational design of our study, and the very strict criteria used 
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for defining the study population requiring that only patients with very early (less than 2 years) 
and progressive skin disease be included. This is in contrast with populations with much longer 
duration of skin disease described in the majority of other studies of SSc disease modifying 
interventions. Another strength of our study is that all patients included were naïve to any 
immunosupressants or anti-fibrotic treatment and received MMF as the only disease modifying 
therapy for the duration of the study.  
The selection of patients with early disease was required in order to mitigate the effects of the 
variable course of SSc and to address the paradigm that early intervention is crucial for effective 
treatment in SSc and other fibrotic diseases. On the other hand, given the relatively low 
sensitivity of the current tools for disease assessment the inclusion of patients with moderate to 
severe disease was important for demonstrating differences induced by the therapeutic 
intervention. 
From the safety perspective MMF related adverse events were mild and well tolerated and only 
three patients required a dose adjustment. Discontinuation of MMF was not necessary in any 
patient. In contrast to the benign pattern of MMF side effects other options for SSc disease 
modification, including cyclophosphamide and bone marrow transplant carry substantial and 
even fatal potential side effects (30,31). Furthermore, the frequency and severity of adverse 
events we observed in this study are not greater than those found in patients with other 
autoimmune diseases or in renal transplant patients treated with MMF. 
We are aware that owing to the non-placebo controlled design of our study it is not possible to 
draw definitive conclusions regarding the efficacy of MMF in modifying SSc disease course. 
However, the remarkable degree of clinical improvement observed in this cohort of progressive 
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SSc of recent onset which was strongly corroborated by histopathological and gene expression 
studies is unlikely to be explained only by the natural evolution of the disease, particularly, in 
this group of patients with very early and progressive disease. Furthermore, given the benign 
safety profile of MMF our findings suggest that therapy with MMF is safe and effective for SSc 
patients with progressive diffuse cutaneous disease of recent onset. 
Given the major limitations and substantial challenges in the study of potential SSc disease 
modifying treatment prospectively designed double-blind studies will be needed to identify 
effective therapeutic interventions for this often devastating disease. 
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Table 1: Sequence of primers utilized for real-time PCR   
  
COL 1A1   Forward: CCTCAAGGGCTCCAACGAG 
COL1A1   Reverse: TCAATCACTGTCTTGCCCCA 
COL1A2   Forward: GGCAAACATGGAAACCGTGGTGAA 
COL1A2   Reverse: GGCAGACCTTGCAATCCATTGTGT 
COL4A1   Forward: TCCTCATTCTGCATCCTGGCTTGA 
COL4A1   Reverse: AAATGGCCCGAATGTGCTTACGTG 
COL11A1  Forward: TTGGTCTGCAGTCGCAATTTCGTG 
COL11A1   Reverse: TGTTACGGTGAAATCCCAGAGCCA 
COL14A1  Forward: AGTCTGGATGGCCACCTACAACAA 
COL14A1   Reverse: TTGGTGACCACCGCATGAAGTTTG 
CTGF   Forward: CTGCAGGCTAGAGAAGCAGAG 
CTGF   Reverse: TTGCCCTTCTTAATGTTCTCTTCC 
FN-1   Forward: TTGATGCCGTTTCCAGCCAAT 
FN-1   Reverse: AAACGCAGGTTGGATGGTGCAT 
αSMA    Forward: TGTATGTGGCTATCCAGGCG 
αSMA    Reverse: AGAGTCCAGCACGATGCCAG 
TGF-β1    Forward: CGAGCCTGAGGCCGACTA 
TGF-β1   Reverse: AGATTTCGTTGTGGGTTTCCA 
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Figure 1 
Assessment of mRSS. Assessment was performed, at initiation of treatment (point 1), at peak of 
skin involvement (point 2), and at last follow up (point 3). 
 
Figure 2  
Assessment of total body surface involvement (BSA) in three patients who had skin biopsies 
before and after MMF treatment. (A) BSA at the initiation of MMF therapy. (B-D) BSA at serial 
follow up evaluations (approximately every three months). 
 
Figure 3 
Histopathology of pre treatment (A and C) and post treatment (B and D) hematoxylin-eosin 
stained skin biopsies. Images are at 100x magnification. A and B show epidermis and upper 
dermis and C and D show lower dermis. Note the remarkable decrease in the thickness and 
compact appearance of the collagen bundles, as well the re-population of dermal structures 
following MMF treatment.  
 
Figure 4 
Relative change in Real Time PCR fibrosis-related gene expression from beginning to end of 
treatment in skin biopsy samples from 3 patients.  Measurement of various collagen genes 
(COL1A1, COL1A2, COL4A1, COL11A1, COL14A1), connective tissue growth factor (CTGF), 
fibronectin 1 (FN-1), alpha smooth muscle actin (αSMA) and transforming growth factor beta 
(TGF-β) are shown.  The horizontal scale shows expression levels (%). Pre-treatment levels were 
normalized to 100%. 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
 
Figure 2 
 
 
 
 
Patient 2 
Patient 1 
Patient 3 
Before Treatment         During Treatment 
Before Treatment                 During Treatment             
            A                     B                   C                 D 
 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 3 
 23 
Figure 4 
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